The efficacy of montelukast in the treatment of cat allergen-induced asthma in children

Wanda Phipatanakul, Anna Nowak-Wegrzyn, Peyton A. Eggleston, Mark L Van Natta, Jana Kesavan, Kenneth C Schuberth, Robert A Wood

Research output: Contribution to journalArticle

Abstract

Background: Montelukast is a leukotriene antagonist approved for the treatment of childhood asthma in children age 2 years and older. There are limited studies on its effects on allergic asthma in children. Objective: We sought to evaluate montelukast's effects on upper and lower airway responses to intense cat allergen exposure. Methods: In a double-blind, placebo-controlled, cross-over trial 18 subjects aged 6 to 14 years with cat-induced asthma were randomly assigned to receive 1 week each of either montelukast or placebo, followed by a 1-hour cat challenge in an environmental exposure unit. Upper and lower respiratory tract symptoms were rated, and spirometry and acoustic rhinometry were performed. Challenges were stopped early if the subject became too uncomfortable or had a greater than 50% decrease in FEV 1. Results: Overall changes in FEV 1 were significantly different with montelukast treatment and remained significant after adjusting for allergen level (P = .02; adjusted P = .01). Lower respiratory tract symptom scores were significantly reduced with montelukast versus placebo (P = .007) but lost significance after adjusting for allergen level (P = .16). Challenge length was significantly longer with montelukast versus placebo (P <.001) and remained significant after adjusting for allergen level (P = .019). Montelukast did not significantly affect upper respiratory responses, as measured by means of symptom scores (P = .43) and changes in acoustic rhinometry (P = .078). Conclusions: Montelukast was significantly more effective than placebo in attenuating lower respiratory responses and extending challenge length when cat-sensitive children with mild persistent asthma were exposed to high levels of cat allergen.

Original languageEnglish (US)
Pages (from-to)794-799
Number of pages6
JournalThe Journal of Allergy and Clinical Immunology
Volume109
Issue number5
DOIs
StatePublished - 2002

Fingerprint

montelukast
Allergens
Cats
Asthma
Placebos
Acoustic Rhinometry
Therapeutics
Respiratory System
Leukotriene Antagonists
Spirometry
Environmental Exposure

Keywords

  • Acoustic rhinometry
  • Cat allergen
  • Cat challenge
  • Montelukast
  • Pediatric asthma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. / Phipatanakul, Wanda; Nowak-Wegrzyn, Anna; Eggleston, Peyton A.; Van Natta, Mark L; Kesavan, Jana; Schuberth, Kenneth C; Wood, Robert A.

In: The Journal of Allergy and Clinical Immunology, Vol. 109, No. 5, 2002, p. 794-799.

Research output: Contribution to journalArticle

@article{3241c1060cc946f1bf43943f96e1fd21,
title = "The efficacy of montelukast in the treatment of cat allergen-induced asthma in children",
abstract = "Background: Montelukast is a leukotriene antagonist approved for the treatment of childhood asthma in children age 2 years and older. There are limited studies on its effects on allergic asthma in children. Objective: We sought to evaluate montelukast's effects on upper and lower airway responses to intense cat allergen exposure. Methods: In a double-blind, placebo-controlled, cross-over trial 18 subjects aged 6 to 14 years with cat-induced asthma were randomly assigned to receive 1 week each of either montelukast or placebo, followed by a 1-hour cat challenge in an environmental exposure unit. Upper and lower respiratory tract symptoms were rated, and spirometry and acoustic rhinometry were performed. Challenges were stopped early if the subject became too uncomfortable or had a greater than 50{\%} decrease in FEV 1. Results: Overall changes in FEV 1 were significantly different with montelukast treatment and remained significant after adjusting for allergen level (P = .02; adjusted P = .01). Lower respiratory tract symptom scores were significantly reduced with montelukast versus placebo (P = .007) but lost significance after adjusting for allergen level (P = .16). Challenge length was significantly longer with montelukast versus placebo (P <.001) and remained significant after adjusting for allergen level (P = .019). Montelukast did not significantly affect upper respiratory responses, as measured by means of symptom scores (P = .43) and changes in acoustic rhinometry (P = .078). Conclusions: Montelukast was significantly more effective than placebo in attenuating lower respiratory responses and extending challenge length when cat-sensitive children with mild persistent asthma were exposed to high levels of cat allergen.",
keywords = "Acoustic rhinometry, Cat allergen, Cat challenge, Montelukast, Pediatric asthma",
author = "Wanda Phipatanakul and Anna Nowak-Wegrzyn and Eggleston, {Peyton A.} and {Van Natta}, {Mark L} and Jana Kesavan and Schuberth, {Kenneth C} and Wood, {Robert A}",
year = "2002",
doi = "10.1067/mai.2002.123530",
language = "English (US)",
volume = "109",
pages = "794--799",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - The efficacy of montelukast in the treatment of cat allergen-induced asthma in children

AU - Phipatanakul, Wanda

AU - Nowak-Wegrzyn, Anna

AU - Eggleston, Peyton A.

AU - Van Natta, Mark L

AU - Kesavan, Jana

AU - Schuberth, Kenneth C

AU - Wood, Robert A

PY - 2002

Y1 - 2002

N2 - Background: Montelukast is a leukotriene antagonist approved for the treatment of childhood asthma in children age 2 years and older. There are limited studies on its effects on allergic asthma in children. Objective: We sought to evaluate montelukast's effects on upper and lower airway responses to intense cat allergen exposure. Methods: In a double-blind, placebo-controlled, cross-over trial 18 subjects aged 6 to 14 years with cat-induced asthma were randomly assigned to receive 1 week each of either montelukast or placebo, followed by a 1-hour cat challenge in an environmental exposure unit. Upper and lower respiratory tract symptoms were rated, and spirometry and acoustic rhinometry were performed. Challenges were stopped early if the subject became too uncomfortable or had a greater than 50% decrease in FEV 1. Results: Overall changes in FEV 1 were significantly different with montelukast treatment and remained significant after adjusting for allergen level (P = .02; adjusted P = .01). Lower respiratory tract symptom scores were significantly reduced with montelukast versus placebo (P = .007) but lost significance after adjusting for allergen level (P = .16). Challenge length was significantly longer with montelukast versus placebo (P <.001) and remained significant after adjusting for allergen level (P = .019). Montelukast did not significantly affect upper respiratory responses, as measured by means of symptom scores (P = .43) and changes in acoustic rhinometry (P = .078). Conclusions: Montelukast was significantly more effective than placebo in attenuating lower respiratory responses and extending challenge length when cat-sensitive children with mild persistent asthma were exposed to high levels of cat allergen.

AB - Background: Montelukast is a leukotriene antagonist approved for the treatment of childhood asthma in children age 2 years and older. There are limited studies on its effects on allergic asthma in children. Objective: We sought to evaluate montelukast's effects on upper and lower airway responses to intense cat allergen exposure. Methods: In a double-blind, placebo-controlled, cross-over trial 18 subjects aged 6 to 14 years with cat-induced asthma were randomly assigned to receive 1 week each of either montelukast or placebo, followed by a 1-hour cat challenge in an environmental exposure unit. Upper and lower respiratory tract symptoms were rated, and spirometry and acoustic rhinometry were performed. Challenges were stopped early if the subject became too uncomfortable or had a greater than 50% decrease in FEV 1. Results: Overall changes in FEV 1 were significantly different with montelukast treatment and remained significant after adjusting for allergen level (P = .02; adjusted P = .01). Lower respiratory tract symptom scores were significantly reduced with montelukast versus placebo (P = .007) but lost significance after adjusting for allergen level (P = .16). Challenge length was significantly longer with montelukast versus placebo (P <.001) and remained significant after adjusting for allergen level (P = .019). Montelukast did not significantly affect upper respiratory responses, as measured by means of symptom scores (P = .43) and changes in acoustic rhinometry (P = .078). Conclusions: Montelukast was significantly more effective than placebo in attenuating lower respiratory responses and extending challenge length when cat-sensitive children with mild persistent asthma were exposed to high levels of cat allergen.

KW - Acoustic rhinometry

KW - Cat allergen

KW - Cat challenge

KW - Montelukast

KW - Pediatric asthma

UR - http://www.scopus.com/inward/record.url?scp=0036251780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036251780&partnerID=8YFLogxK

U2 - 10.1067/mai.2002.123530

DO - 10.1067/mai.2002.123530

M3 - Article

C2 - 11994702

AN - SCOPUS:0036251780

VL - 109

SP - 794

EP - 799

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -